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Abstract
Background: Thiazolidinediones exert anti-inflammatory and anti-oxidative roles and attenuate
atherosclerosis by mechanisms partially independent of their metabolizing actions. High doses of
angiotensin type 1 receptor (AT1R) blocker losartan (LST) seem to promote fat cell formation by
preserving PPARγ activity.
Methods: C57BL/6J diet-induced atherosclerotic susceptible mice randomly received a normal or
a high-fat high-cholesterol (HFHC) diet and were treated with rosiglitazone (RG), LST or a vehicle
for 12 weeks.
Results: HFHC was associated with increased PPARγ gene expression without an over regulation
of PPARγ responsive genes, whereas RG and LST treatments were found to maintain PPARγ
activity without resulting in increased PPARγ gene expression. A better anti-inflammatory and
antioxidant profile in mice treated with RG regarding LST was observed in spite of a similar PPARγ
preserved activity. Chromatin immunoprecipitation (ChIP) assays revealed that animals under
HFHC diet treated with RG showed a significant nuclear factor erythroid 2-like 2 (Nrf2)-dependent
down-regulation of the expression of the CD36 gene.
Conclusion: The PPARγ agonist RG exerts antioxidant properties that significantly reduced Nrf-
2-dependent CD-36 up-regulation in mice under HFHC diet. Because LST treatment was also
associated with a preserved PPARγ activity, our data suggests that these RG antioxidant effects are
partially independent of its PPARγ metabolizing properties.
Background
Superoxide generation occurs in conditions such as hyper-
tension, hypercholesterolemia, diabetes, and cigarette
smoking. Oxidant stress alters many functions of the
endothelium which, associated with traditional risk fac-
tors, triggers early vascular inflammation and a predispo-
sition to atherosclerosis [1-3]. Low-density lipoproteins
(LDLs) are susceptible to oxidative damage. Oxidative
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role in initiation of the atherosclerotic process [1,4,5]. Ox-
LDLs are taken up via different scavenger receptors. The
CD36 scavenger receptor constitutes the major ox-LDL
receptor [6]. Studies employing transgenic and knock-out
mice have demonstrated that CD36 is proatherogenic
according to observations that targeted disruption of the
gene was protective against atherosclerosis [7]. Compo-
nents of ox-LDL activate peroxisome proliferator-acti-
vated receptor γ (PPARγ) resulted in an up-regulation of
the CD36 scavenger receptor [8,9].
Thiazolidinediones (TZDs) are PPARγ agonists that
improve insulin sensitivity, reduce triglyceride levels and
decrease the risk of atherosclerosis in diabetic patients.
TZDs also exert direct effects on vascular wall cells [10-
12]. TZDs treatments inhibit intimal lesions [13], sup-
press monocyte elaboration of inflammatory cytokines
[14], macrophage activation [15], and the expression of
cell adhesion molecules [16]. TZDs also increase the
mRNA expression of the proatherogenic CD36 gene.
PPARγ seems to be determinant in the CD36 gene regula-
tion as deduced from macrophages derived from mice in
which the PPARγ gene has been "floxed out" [17]. How-
ever, most authors suggest that the CD36-increasing
effects of TZDs might be overwhelmed by the antiathero-
genic effects of other factors. Rosiglitazone (RG) is a TZD
that possesses several anti-inflammatory properties dem-
onstrating a protective action in regulating atherosclerosis
development [18-20].
Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a
member of the Cap 'n' Collar family of basic region-leu-
cine zipper transcription factors. Transcription factor Nrf2
is a major regulator of genes encoding phase 2 detoxifying
enzymes and antioxidant stress protein in response to
electrophilic agents and oxidative stress. Evidence that ox-
LDLs and some lipid hydroperoxides contained in ox-LDL
enhanced nuclear levels of Nrf2 in macrophages has been
reported [21]. This increase results in an up-regulation of
the scavenger receptor CD36 and antioxidant stress pro-
teins [21]. Thus, Nrf2 appears as an additional transcrip-
tion factor regulating CD36 gene expression.
Adipocyte differentiation seems to be linked to an
improvement of insulin sensitivity [22]. Sharma et al [23-
25] proposed the hypothesis that blockade of the renin-
angiotensin system prevents diabetes by promoting the
recruitment and differentiation of adipocytes. In vitro
studies further demonstrate that several angiotensin
receptor blockers or their metabolites induce PPARγ activ-
ity and opposite, ligand activated-PPARγ suppressed AT1R
gene transcription [25-27]. Paradoxically, studies reveal
that a moderate reduction of PPARγ activity as observed in
heterozygous PPARγ-deficient mice, or the Pro12Ala pol-
ymorphism in human PPARγ gene, prevent insulin resist-
ance and obesity induced by a high-fat diet [28]. This
reduction is thought to occur because PPARγ expression is
regulated by nutritional state [29]. Oxidative and inflam-
matory mediators as those produced in long-term high-fat
high-cholesterol (HFHC) diets are known to be inducers
of different responses that regulate PPARγ gene activity.
The activity of PPARγ can be finely tuned through integra-
tion of diverse phosphorylation events [29-32].
The aim of the present study was to show that RG and
losartan (LST) treatments preserved the liver PPARγ activ-
ity in mice that were fed with a HFHC diet. On the con-
trary, a loss of PPARγ activity was observed instead of an
increase of the PPARγ gene expression in the untreated
hypercholesterolemic control mice. Lipid hydroperoxides
levels and the relative expression values of the inflamma-
tory mediators inducible nitric oxide synthase (iNOS) and
Interleukin-6 (IL-6) genes were diminished in mice
treated with RG with respect to LST treated mice. These
findings were suggestive of RG additional properties inde-
pendent of its metabolizing actions. A difference in the
CD36 gene expression level between treated groups was
observed. Because oxidative stress activates Nrf2
responses and recently has been described as the essential
contribution of Nrf2 to the CD36 gene expression, we also
investigated whether Nrf2 mediates the CD36 gene up-
regulation observed in the LST group. A chromatin immu-
noprecipitation (ChIP) assay revealed that in the RG pre-
vents Nrf2-dependent CD36 up-regulation.
Methods
Animals
Two-month old female inbred strain C57BL/6J and
C3HeJ/6J mice that differ strikingly in aortic fatty streak
development when fed a high-fat diet were housed at
25°C on a 12-hour light/dark cycle and provided with
food and water ad libitum. At day 0, C57BL/6J animals
were maintained either on a chow diet or a high-choles-
terol diet containing 15% fat, 1.25% cholesterol, and
0.5% cholic acid (Panlab, S.L., Barcelona, Spain) for 12
weeks. Twenty-three mice per group were randomly
selected in one of the following groups: group 1 (control)
was maintained on chow diet; group 2 (control) was
maintained on high-cholesterol diet; group 3 constituted
C57BL/6J mice maintained on high-cholesterol diet that
received RG administered at 25 mg/Kg/day; and group 4
was composed of C57BL/6J mice on high-cholesterol diet
that received LST administered in the drinking water at
100 mg/L. RG was administered by food and was moni-
tored every day. Similarly, the water consumption in the
LST group was monitored weekly. Each mouse was esti-
mated to drink 1.5 ml of water/10 grams of body weight/
day. A group of 25 C3HeJ female mice fed on high-choles-
terol diet was also created (group 0).Page 2 of 15
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ance with the animal welfare guidelines of the Hospital
Universitario de Gran Canaria Dr. Negrín; the national
guide (Royal Decree 223/1988) and the international
guide (Guide for the Care and Use of Laboratory Animals,
published by the US National Institutes of Health) for the
use and care of animals for experimentation. All investiga-
tors directly involved in the handling of animals possess
the relevant approvals from the Ministry of Agriculture,
Fisheries and Food of the Directorate General of Animal
Husbandry of the Canary Islands Government in the B
and C categories (Royal Decree 1201/2005).
Animals were anesthetized with 5 μl per grams of body
weight using an anesthetic cocktail of Ketolar (ketamine
hydrochloride at 50 mg/ml) (Parke-Davis, S.L.; Barcelona,
Spain) and Rompún (xylazine at 2% administered at 2.5
mg/ml; Bayer Health Care, AG, Germany) in saline solu-
tion. Blood samples were collected by cardiac left ven-
tricular punction in three animals per group, chosen
between housed at days 1, 25, 50, 75, and 100. At the end
of the study period (day 105) five mice per group were
anesthetized and transcardially perfused with saline fol-
lowing tissue samples collection. Liver samples were
obtained, snap-frozen by immersion in liquid nitrogen
and stored at -20°C until use.
Analysis of plasma lipids and lipid peroxidation
Blood was collected from 6-hour fasted animals and
plasma samples were stored at -70°C. Insulin was meas-
ured by the Abbott kit insulin (Abbott Laboratories, USA).
Plasma levels of total cholesterol (TC), triglyceride (TG)
and HDL-cholesterol were measured enzymatically by
using Wako kits. Total plasma lipid hydroperoxide
(LOOH) content was calculated by the Xylenol Orange
(FOX) assay as described elsewhere [33] and analyzed
after being mixed with copper sulphate at a final concen-
tration of 10 μM at 37°C for 24 h, using triphenyl phos-
phine (TPP) for signal authentication. The absorbance of
the supernatants was monitored at 560 nm and the
hydroperoxide content determined using a molar absorp-
tion coefficient of 4.3 × 104 M-1.cm-1 or by reference to an
H2O2 standard curve.
LOOH content was also measured in the supernatant of
cultured cells by the modified method of Auerbach [34].
To 40 μl aliquots were added to a 96-well microtiter plate
containing ethanol (10 μL) and N-benzoyl leucomethyl-
ene blue (LMB) color reagent (100 μL). The LMB reagent
was prepared with 5 mg of LMB (Tokyo Kasei Kogyo) dis-
solved in 8 mL of N,N-dimethyl-formamide and 90 mL of
0.05 mol/L potassium phosphate buffer, pH 5, 1.4 g of
Triton X-100, and 5.5 mg of hemoglobin. Linoleic acid
hydroperoxide (13-hydroperoxy-9,11-octadecadienoic
acid, ranging from 1 to 20 nmol in 10 μL ethanol) was
added as a standard to wells containing saline (40 μL) and
LMB. After 40 minutes at room temperature, the standards
and samples were read at 650 nm using a microtiter plate
reader. A standard curve for absorbency versus LOOH
concentration was generated, and the hydroperoxide lev-
els in samples were determined from this curve.
Analysis of Paraoxonase/arylesterase activities
Paraoxonase (PON p. ase) and arylesterase (PON ar.ase)
activities were evaluated by previously described methods
[35,36].
Analysis of Total Nitric Oxide Metabolites
Plasma samples were filtered through Microcon YM-10
columns (Millipore). Total nitric oxide metabolites con-
centration was evaluated in sample columns effluent by
using a colorimetric kit assay according to the manufac-
turer instructions (R & D Systems).
Cell-Free Dichlorofluorescein (DCF) assay
Total HDL was prepared by precipitation using the DS1
reagent. DS1 was prepared dissolving in water 10 mg/L
dextran sulphate (Dextralip®50, Sigma), 0.5 mol/L MgCl2,
and 0.05% sodium azide. The protein content of precipi-
tated HDL was determined and HDL samples were subse-
quently adjusted to similar protein content with saline.
The cell-free Dichlorofluorescein (DCF) assay was per-
formed essentially as described [37]. Ten microliters of
DCFH-DA (Molecular Probes, Eugene, OR) dissolved
methanol were placed in polypropylene tubes and evapo-
rated under vacuum. A similar procedure was conducted
following addition of L-α-1-palmitoyl-2-arachidonoyl-sn-
glycero-3-phosphocholine (PAPC) (10 μl at 2.5 mg/ml in
chloroform) and 20 μl of HPODE at 0.5 mg/ml in etha-
nol. Finally, 25 μl of saline or HDL at 500 μg/ml was
added to each tube and the volume adjusted to 1 ml with
saline. Samples were incubated for 2 hours at room tem-
perature in the dark before counting in a FLx800 Micro-
plate Fluorescence Reader. Authentic L-α-1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine (PAPC) was
obtained from Avanti Polar Lipids (Alabaster, AL) and
13(S)-HPODE was obtained from Biomol (Plymouth
Meeting, PA).
Cell Culture and Stimulation
3T3-L1 pre-adipocytes were grown in Dulbecco's modi-
fied Eagle medium (DMEM) to confluence and differenti-
ated with 0.5 mM of isobuthylmethylxanthine (IBMX), 1
μM dexamethasone, 10 μg/ml insulin and 5% calf serum
for 48 hours essentially as described [26]. Insulin was
maintained for 2 additional days in the differentiated con-
trol cells group. For the remaining groups, cells were
washed with PBS and incubated in medium containing
RG at 40 μM, LST at 100 μM, or a vehicle for 5 days.Page 3 of 15
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incubated with RG and LST were exposed to oxidized
PAPC (ox-PAPC) for 24 h. Oxidized PAPC (ox-PAPC) was
prepared and isolated as described [38]. 3T3-L1 preadi-
pocyte and adipocytes were stained with Oil Red O essen-
tially as described [39].
Analysis of mRNA levels by real-time PCR
Total RNA was isolated from mice liver and cells by the
Chomczynski method. Hepatic and cultured cells cDNAs
was synthesized using MMLV (Roche Diagnostics) follow-
ing the instructions provided by the manufacturer. Real-
time PCR was performed on a LightCycler device using the
FastStart DNA Master SYBR Green I (Roche Diagnostics)
according to the provided protocol. Amplifications of
PPARγ gene and of the PPARγ target gene SCARB1 were
performed using the primers pairs: 5'-TTTTCAAGGGT-
GCCAGTTTC-3' and 5'-AATCCTTGGCCCTCTGAGAT-3'
spanning 198 base pairs of the exon 6 of the PPARγ gene
[GenBank accession number NM_011146] and 5'-
GAAAAAGCGCCAAGTACAGC-3' and 5'-CAGGCTGT-
GGGAACTCTAGC-3' spanning 248 bp of the SCARB1
gene [GenBank NM_016741]. Fragments of the CD36;
Paraoxonase 1 (PON1); 5-lipoxygenase (Alox5); 15 lipox-
ygenase type A (Alox15) and 15 lipoxygenase B (Alox15b)
genes were amplified using the following primer pairs: 5'-
GAGCAACTGGTGGATGGTTT-3' and 5'-GCAGAAT-
CAAGGGAGAGCAC-3' which yields a 207 bp fragment of
the CD36 gene [GenBank NM_007643]; 5'-CAC-
CCGTCTCGATTCCTTTA-3' and 5'-CAGCCTGTCCATCT-
GTCTCA-3' that amplified a 178 bp fragment of the PON1
gene [GenBank NM_011134]; 5'-GTGCTGCTTGAGGAT-
GTGAA-3' and 5'-CTACGATGTCACCGTGGATG-3' that
amplified a 235 bp fragment of the Alox5 gene [GenBank
L42198]; 5'-GATTGTGCCATCCTTCCAGT-3' and 5'-CAG-
GGATCGGAGTACACGTT-3' that amplified a 186 bp frag-
ment of the Alox15 [GenBank NM_009660]; 5'-
GCTAAAGCATGCCAGTGTGA-3' and 5'-GCTCTGAT-
TAACGGCTTTGC-3' that yield a 229 bp fragment of the
Alox15b gene [GenBank NM_009661]. Fragments of the
IL-6, CYBA (p22phox), eNOS and iNOS genes were
amplified using previously described primers [40,41].
When linearity and efficiencies were similar between tar-
gets and the reference amplified glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) fragment, relative
expression analyses were performed by the comparative
threshold cycle quantitation method. Alternatively, tar-
gets and the GAPDH fragment were analyzed by using
serial dilutions of pooled cDNA and then applying the
standard curve quantitation method. The 223 bp frag-
ment of the GAPDH gene was amplified with the follow-
ing primers: 5'-ACA CAT TGG GGG TAG GAA CA-3' and
5'-AAC TTT GGC ATT GTG GAA GG-3' [GenBank
NM_008084]. Primers design was done by using the pub-
lic domain software Primer3 [42].
Chromatin immunoprecipitation assays
Liver samples (≈ 0.05 grams per mouse) were allowed to
thaw on ice in serum-free DMEM and then cross-linked
with 5% formaldehyde for 5 minutes. Liver fragments
were homogenized and nuclear and cytosolic fractions
extracts prepared by using a nuclear extraction kit from
Active Motif according to the manufacturer instructions.
Nuclear lysates were sonicated on ice. As a positive control
(input) undiluted aliquots were retained for further
processing in parallel with all the other samples at the
reversal of the crosslinked step. ChIP assays were per-
formed adding to the chromatin complexes 10 μl of
αNrf2-C20 or PPARγ (H-100) antibodies (Santa Cruz) or
without antibody overnight at 4°C. DNA samples were
recovered and subjected to analysis by real time PCR
amplification. Primers used were specifically designed to
amplify a putative antioxidant response element (ARE) in
the CD36 gene promoter and a putative peroxisome pro-
liferator response element (PPRE) in the Apolipoprotein
A-I (Apo A-I) gene promoter by using the software
Primer3. Primers flanking a PPRE at iNOS gene were as
described [43]. A putative CD36 ARE (RTGAYnnnGC) site
was identified located between base positions 1425 to
1434 in the CD36 gene promoter [GenBank AF434766]
and primers flanking this sequence were designed with
the sequences: 5'-TGCTCTGAGCTCTACCCTCTG-3' and
5'-TCTGTCCCCTCTTTTGCAGT-3'. The CD36 promoter
sequence was analyzed and completed for gap and errors
considering the previously published information
[44,45]. Mouse sequence data homologous to the Apo A-
I 5' UTR region of the Rattus norvegicus Apo A-I promoter
sequence [GenBank X54210] was identified after a BLAST
search. A large fragment encompassing 562 bases from
171971 to 172532 of the Mus musculus chromosome 9
sequence, clone RP24-302M3 [GenBank AC116503],
matched with the promoter sequence and was subse-
quently explored to find potential PPRE binding sites. A
consensus sequence of the form RG(G/T)TCA was found.
The identified sequence AGTTCAAGGATCA constitutes a
DR1 element of the form with a perfect RG(G/T)TCA 5'-
motif and an imperfect 3'-motif. Primers flanking a puta-
tive PPRE in the apo A-I promoter regions used were 5'-
TCTGGGTGTCCAGCTCTTCT-3' and 5'-CCTGTTT-
GCCCACTCTGTTT-3'. Similarly, a BLAST search was per-
formed using the SCARB1 promoter region of Rattus
norvegicus [gi:50881992]. A fragment that was in common
with the BAC clone of the Mus musculus chromosome 5
[gi:71533446] was selected. A PPRE site was identified in
the fragment encompassing 360 base pair. This sequence
was used to design primers flanking the SCARB1 pro-
moter region with the sequences 5'-TTGTGTCCTGAGT-
GGAATGC-3' and 5'-AGCAGGGTGGTAGGGACTCT-3'.
The CD36, SCARB1 and apo A-I promoter regions were
also amplified by standard PCR and subjected to gel elec-
trophoresis. Agarose bands were excised, purified (QIA-Page 4 of 15
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310 device using the BigDye® v. 3.1 Terminator Cycle
Sequencing Kit according to the manufacturer instruc-
tions (Applied Biosystems).
Statistical analyses
Quantitative variables are presented as mean ± SEM
unless otherwise specified and qualitative variables as per-
centages. Pair wise related group comparisons were per-
formed using the Wilcoxon test whereas the Mann-
Whitney U-test was used for comparisons of unrelated
groups. The level of significance was set at P < 0.05.
Results
Lipid profile and HDL concentration between treated 
groups
No differences in the food and water consumption were
visible among animals of one experimental group or
between experimental or control groups. There were no
significant differences in insulin levels between treated
and untreated mice.
Animals that were fed on HFHC treated with RG showed
a significant difference in HDL-cholesterol level with
respect to mice fed only on HFHC diet at the beginning (p
= 0.02) and at the end of the study period (p = 0.019).
Mice treated with RG showed a significant increase in
HDL-cholesterol levels between day 1 and day 100 (p =
0.016) (Figure 1b). No differences in total cholesterol and
triglycerides levels were observed.
As shown in Figure 1d, we found lower, albeit not signifi-
cant (p = 0.06), levels of total LOOH in mice fed on HFHC
diet treated with RG with respect to those observed in
mice fed on HFHC diet. Also, lower levels of LOOH were
observed in the RG group with respect to mice treated
with LST or even with respect to the C3HeJ control group.
A significant difference in LOOH content in the RG group
between days 1 and 100 (p = 0.02) was observed.
As pointed out above, raised HDL levels in RG with
respect to LST treated mice were observed. Increase in
apoA-I gene, a main determinant of HDL concentration
levels, might occur after RG treatment because of its abil-
ity to act on PPRE elements located at the apoA-I gene
which might also preserve HDL-associated antioxidant
properties [18]. Therefore, these two possibilities were
analyzed as follows. First, we tested the ability of isolated
HDL to inhibit the oxidation of PACP by HPODE by the
DCF cell-free assay. Fluorescence signal comparisons
between HDL obtained from either C57BL/6J mice on a
chow diet and C57BL/6J that fed a HFHC between day 1
and day 100 were significant (Figure 2a). Therefore, both
time elapsed and hypercholesterolemic diet were associ-
ated with a reduction of the HDL antioxidant properties.
As deduced from Figure 2a, we observed that both RG and
LST treatment preserved the antioxidant properties of
HDL. Interestingly, no differences in the HDL-linked
Paraoxonase and arylesterase activities as well as in the
PON1 gene expression were observed between pharmaco-
logical treated groups (not shown). Second, the Apo A-I
proximal promoter levels were evaluated after PPARγ
ChIP assay as described in our methods. As depicted in
Figure 2b, experiments demonstrated respectively a
63.5% and a 92.5% of DNA amplified after ChIP in the
LST and RG treated mice groups with respect to mice fed
on HFHC diet. The difference between both pharmaco-
logical treated animal groups was not significant. This
finding suggested that the PPARγ-mediated transcription
of apo-A-I was not different in treated groups and interest-
ingly that a preserved PPARγ activity was also present in
the LST group.
PPARγ and the levels of the PPARγ-responsive gene 
SCARB1 were similar between treated groups
As seen in Figure 3a at day 100, a significant increase in
PPARγ gene relative expression was observed in animals
fed on HFHC diet with respect to chow (p = 0.01). No dif-
ference was observed in the PPARγ expression levels
between LST and RG treated mice. Gene expression levels
of the PPARγ response gene SCARB1 were next evaluated.
At day 100 a significant decrease in SCARB1 gene expres-
sion in mice fed on HFHC diet with respect to mice fed on
chow diet (p = 0.02) was observed. SCARB1 expression
levels were significantly higher in hypercholesterolemic
mice treated with LST in respect to untreated HFHC fed
mice. Jointly considered PPARγ and SCARB1 expression
data are suggestive of a preserved PPARγ activity in both
pharmacological treated groups. To specifically evaluate
this PPARγ preserved activity, ChIP assays were con-
ducted. Following PPARγ-mediated immunoprecipitation
assays revealed that there was a 38% reduction in the
amplified level of SCARB1 promoter region that was
accessible to PPARγ in mice fed with a HFHC diet com-
pared to mice fed a control low-fat diet (p = 0.109) (Figure
3c). It seems that in mice fed on HFHC diet, in spite of a
significant increase in the PPARγ expression levels, this
nuclear receptor seems to be unable to efficiently bind to
the PPRE site in the SCARB1 gene. In this context, we
observed that in those animals fed on HFHC diet that
were also treated with LST or RG, the amplified values of
SCARB1 DNA were respectively 162% and 265% higher
than those in C57BL/6J fed a HFHC diet. The difference
between LST and RG groups did not reach statistical sig-
nificance.Page 5 of 15
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treated mice; rosiglitazone prevents Nrf2-dependent CD36 
up-regulation
Increased gene expression level of CD36 gene was shown
in animals that were fed on HFHC diet with respect to
chow-fed mice (p = 0.02) (Figure 4a). We observed a sig-
nificant increase in CD36 relative expression level in mice
treated with LST with respect to mice control groups feed-
ing on either chow or HFHC diet (p < 0.05 for both). Mice
that were fed on HFHC diet treated with RG showed
higher but not significant CD36 relative gene expression
level regarding chow-fed mice. A significant reduction in
CD36 expression levels was observed in RG treated mice
with regard to both HFHC control mice and HFHC mice
treated with LST (p < 0.05 for both).
Previous results suggested similar levels of PPARγ activity
between our treated groups. Studies have established the
role of Nrf2 as a novel signalling pathway involved in the
regulation of the CD36 gene. Evidence that ox-LDLs and
certain oxidized lipids of LDL particles are inducers of
Nrf2 [21] has been reported. Thus, we next explored the
possibility that Nrf2 could be playing a pivotal role in the
observed diminished total plasma LOOH levels in mice
that fed a HFHC diet treated with RG with respect to either
LST treated and untreated hypercholesterolemic mice as
well as in the observed diminution in the relative expres-
sion levels of CD36 gene in the RG mice group with
respect to the mice LST group. To address this possibility,
ChIP assays using an antibody against Nrf2 followed with
real-time analysis of the ARE site at the CD36 gene pro-
moter identified as described in the methods were per-
Mean total cholesterol (a), HDL-cholesterol (b), triglycerides (c) and lipid hydroperoxides (d) content in plasma of study groupsFig re 1
Mean total cholesterol (a), HDL-cholesterol (b), triglycerides (c) and lipid hydroperoxides (d) content in 
plasma of study groups. Triplicate measurements were taken in three animals per group before the onset of the study 
period (day 0), at day 1 and each 25 days elapsed after completing 100 days. Inter-group comparisons were made at day 1 and 
at day 100 and intra-group between days 1 and 100. Data are expressed as mean ± SD.Page 6 of 15
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amplified CD36 gene promoter region was observed in
animals fed with a HFHC diet with respect to control
chow mice (p < 0.05) (Figure 4b); similarly, mice treated
with LST showed increased amplification levels of the
CD36 promoter region regarding chow mice (p < 0.05 for
Treatments preserve HDL antioxidant properties and apolipoprotein A-I-(apo A-I)-PPARγ-mediated gene expressionFigure 2
Treatments preserve HDL antioxidant properties and apolipoprotein A-I-(apo A-I)-PPARγ-mediated gene 
expression. (a). Fluorescence intensity (arbitrary units) was determined as described in Methods. There was no difference in 
the fluorescence signal levels measured of the HDL isolated from mice under control diet with respect to that obtained from 
mice that fed a HFHC diet after 1 day elapsed; thus the average fluorescence value obtained of the HDL from both groups was 
taken as "Day 1" reference value. Data are mean ± SD from thee separate experiments. (b). ChIP with a PPARγ antibody of 
study groups were used to amplify an apo A-I promoter fragment. ChIP figures percentages indicate increments or decrements 
regarding C57BL/6J mice fed HFHC diet. Data of C57BL/6J mice fed chow diet was established as 100%.Page 7 of 15
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nificant lower amplification levels of the CD36 promoter
fragment with respect to the amplification levels obtained
in the control chow-fed group (Figure 4b). Remarkably, as
depicted in Figure 4b, we found a 125.8% decrease in
Treatments preserve PPARγ activity and PPARγ responsive gene expressionFigure 3
Treatments preserve PPARγ activity and PPARγ responsive gene expression. (a) PPARγ mRNA relative expression 
in pooled liver samples from analyzed groups normalized to GAPDH expression. Results are expressed as mean ± SEM per-
centage of mean values obtained from equal numbers of C57BL/6J and C3He/6J mice. *P < 0.05. (b). SCARB1 mRNA relative 
expression in liver samples from analyzed groups normalized to GAPDH expression. *P < 0.05 (c). ChIP with a PPARγ antibody 
of study groups was used to amplify a SCARB1 promoter fragment. ChIP figures percentages indicate increments or decre-
ments regarding C57BL/6J mice fed HFHC diet. Data of C57BL/6J mice fed chow diet was established as 100%.Page 8 of 15
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Rosiglitazone prevents Nrf2-depedent CD-36 up-regulation in hypercholesterolemic C57BL/6J miceFigure 4
Rosiglitazone prevents Nrf2-depedent CD-36 up-regulation in hypercholesterolemic C57BL/6J mice. (a) CD36 
mRNA relative expression in pooled liver samples from analyzed groups normalized to GAPDH expression. *P < 0.05. (b) ChIP 
with an Nrf2 antibody of study groups was used to amplify a CD36 promoter fragment. ChIP figures percentages indicate incre-
ments or decrements regarding C57BL/6J mice fed HFHC diet. Data of C57BL/6J mice fed chow diet was established as 100%. 
(c) Quiascent day-5 adipocytes incubated with RG and LST were treated with ox-PACP for additional 24 h. RNA was isolated 
to measure adipose protein 2 by conventional PCR and CD36 expression using real-time PCR. Values were normalized to 
GAPDH expression. Figure bar plots represent mean ± SEM percentage from vehicle-treated cells of at least 4 experiments 
with duplicate measurements.
Cardiovascular Diabetology 2008, 7:3 http://www.cardiab.com/content/7/1/3hypercholestelomic mice treated with RG with respect to
LST treated mice (p = 0.02).
Rosiglitazone prevents CD36 up-regulation in 3T3 
differentiate cells exposed to ox-PACP
Adipocyte differentiated cells were treated with LST or RG
at the doses and times previously described. Differentia-
tion was confirmed by the increased oil-red staining and
evaluating the relative expression of the adipogenic
marker gene adipose protein 2 (ap2). Statistical compari-
sons revealed that cells treated with the differentiation
cocktail showed significant higher level of ap2 amplified
fragment regarding all analyzed groups. Those LST or RG
treated cells showed similar levels of ap2 gene. Cells
treated with both RG and LST showed diminished CD36
expression levels than those observed in differentiated
untreated cells (p < 0.05 for both) (Figure 4c). However,
no difference between both treated cell groups was
observed. Then, we tried to simulate in vivo oxidative con-
ditions by exposing treated cells to ox-PAPC. Cells treated
with LST exposed to ox-PAPC showed no difference in the
CD36 relative expression levels with respect to its differen-
tiated cells group (p = 0.07) (Figure 4c). However, a statis-
tical significant reduction in CD36 relative expression
levels in cells treated with RG exposed to ox-PAPC with
respect to differentiated control non-exposed cells (p =
0.03) was observed (Figure 4c).
Moreover, we found that the LOOH content in the super-
natant of differentiated cells was significantly increased
with respect to its undifferentiated controls (p = 0.007).
This increase positively correlated with the CD36 gene
expression levels (p = 0.034). On the contrary, we
observed that both LST and RG treatments produced a sig-
nificant decrease in the LOOH content with respect to dif-
ferentiated cells group (p = 0.044 and p = 0.001,
respectively). Again, no difference in LOOH levels was
observed between treated cells. Cells treated with RG or
LST exposed to ox-PACP showed mean lower levels of
LOOH than those obtained in unexposed cells treated
only with LST or RG (p < 0.001 for both). Statistical com-
parison showed no differences between either ox-PACP
treated group. Notably, this occurred in spite of the fact
that CD36 gene expression levels were observed to be
higher in cells treated with LST plus ox-PACP regarding
cells treated with RG plus ox-PACP.
Assessing the relative expression of Nitric Oxide Synthase 
and Interleukin-6 genes
RG treated mice showed a statistically significant reduc-
tion of the iNOS relative gene expression, with respect to
both chow-fed animals and HHFC-fed mice treated with
LST (p < 0.05 for both) (Figure 5a). IL-6 relative gene
expression values although lowers in RG treated mice did
not differ among analyzed groups (not shown).
Mean eNOS gene expression values in mice fed on a
HFHC diet treated with RG or LST were smaller than those
obtained in HFHC fed control mice. This reduction was
significant for the comparison of mice treated with RG
with respect to HFHC-fed control group (p = 0.04) (Figure
5b). Accordingly, group comparison showed that plasma
nitric oxide metabolites values were found to be reduced
in RG regarding LST treated mice (p = 0.02).
Differences in the iNOS gene expression and its PPARγ 
dependence
ChIP assays using an antibody against PPARγ followed by
real-time amplification of an iNOS gene fragment flank-
ing the recently identified PPRE [43] at iNOS gene showed
a 119% increase in average mean amplification values in
mice under HFHC diet with respect to those obtained in
chow-fed mice (-100%) (p = 0.1) (Figure 5c). In line with
our previous results, amplification levels were higher after
amplifying DNA from PPAR immunoprecipitates
obtained from HFHC-fed mice treated with LST and RG
(199% and 168% respectively). Comparison between
treated groups yielded no difference (p > 0.05) (Figure
5c). Thus, although PPARγ expression levels were not
increased in these groups regarding mice fed only on a
HFHC diet, the ability to access PPRE binding sites in tar-
get genes seems to be preserved in both treated mice
groups. Thus, the observed iNOS up-regulation in LST
treated mice seems to be independent of the PPAR pre-
served activity.
Discussion
In this study we demonstrated that the administration of
RG or LST to diet-induced atherosclerosis susceptible mice
fed a HFHC diet preserves to the same extent in both
groups the activity of nuclear receptor PPARγ Conclusions
derived from the analysis of the expression levels of
PPARγ responsive gene SCARB1 and the amplification lev-
els of PPRE binding sites of target genes amplified after
ChIP which were shown to be approximately equal.
Previous studies in two murine models of atherosclerosis
have shown that treatment with PPARγ agonists protected
against the development of atherosclerosis [17-19]. How-
ever, lessons obtained from murine models of atherogen-
esis with or without diabetes should be viewed with
caution given the known differences between vascular
lesions from those animal models compared to those seen
in humans [46]. Interestingly, we find that in spite of the
similarly preserved PPARγ activity, RG administration was
associated with a better "antiatherogenic" profile than this
found in animals treated with LST exposed to the same
diet. Thus, we found that hypercholesterolemic mice
treated with RG showed inferior levels of total peroxidized
lipids than those measured in hypercholesterolemic mice
treated with LST. Moreover, when the relative gene expres-Page 10 of 15
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found lower expression levels in mice treated with RG
with respect to those obtained in LST treated mice. Values
reached significance for iNOS gene expression. Further
enhancements of iNOS expression in mice that fed a
HFHC diet treated with RG with respect to LST treated
Treatments modified iNOS gene expression while PPARγ-mediated iNOS amplification levels were similarFigure 5
Treatments modified iNOS gene expression while PPARγ-mediated iNOS amplification levels were similar. (a) 
iNOS mRNA relative expression in pooled liver samples from analyzed groups normalized to GAPDH expression. *P < 0.05. 
(b) eNOS mRNA relative expression in pooled liver samples from analyzed groups normalized to GAPDH expression. Results 
are expressed as mean ± SEM percentage of mean values obtained from equal numbers of C57BL/6J and C3He/6J mice. *P < 
0.05. (c) ChIP with a PPARγ antibody of study groups was used to amplify an iNOS promoter fragment. ChIP figures percent-
ages indicate increments or decrements regarding C57BL/6J mice fed HFHC diet. Data of C57BL/6J mice fed chow diet was 
established as 100%.Page 11 of 15
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activity as deduced from ChIP assays.
Because there is a second target of PPARγ activation, the
liver X receptor α whose activity was not analyzed in our
work, care must taken with the interpretation of our
results. Nevertheless, we suggested possible additional
antioxidants and anti-inflammatory effects of the RG that
seem to be partially independent of its action on PPARγ
activity. It is important to note that in our experimental
model, we also observed a difference in the HDL-choles-
terol concentration level. Values were higher in mice
treated with RG compared to those found in the LST
treated group. Besides the key role of HDL particles in the
regulation of cholesterol homeostasis by enhancement
reverse cholesterol transport, it is known that HDL also
exhibits antioxidant and anti-inflammatory properties
that participate in its general antiatherogenic effect. The
antioxidant ability of HDL is due to the apoprotein moi-
ety and to the presence of associated enzymes [47]. The
apoA-I has also been shown to be capable of removing
seeding molecules from LDL, thus preventing the oxida-
tion of LDL-derived phospholipids [38,48]. Therefore we
considered if this observed HDL increase would justify by
itself the best antioxidant profile obtained in mice treated
with RG as compared to LST treated mice. We showed that
the HDL particles isolated from both treated animal
groups exhibited similar characteristics regarding their
capacity to avoid the oxidation of PACPC by HpODE.
However, these experiments do not exclude the fact that
perhaps this difference in the HDL levels could be relevant
by itself. The determinant role of apo A-I in increasing
HDL levels has been clearly established in apoE-knockout
mice [49]. According to this, it could be possible that non-
evaluated differences in apo A-I concentrations, and there-
fore differences in HDL concentrations and activities,
were justified by other transcriptional regulators that were
not analyzed in our work. Interestingly, because of the
existence of a peroxisome proliferator-responsive element
(PPRE) at the apo A-I gene, it also could be possible that
as suggested [18] the apo A-I gene might be positively reg-
ulated by PPARγ. This possibility was analyzed in our
work. Thus, because we observed similar of PPARγ-medi-
ated apo A-I gene transcription we concluded that the apo
A-I is certainly positively regulated by PPARγ agonists but
also indirectly we concluded that the PPARγ activity was
preserved in both treated animal groups.
The role of PPARγ as a transcriptional regulator of CD36
gene expression has been previously established [9,17].
Surprisingly, we observed a statistical difference in the rel-
ative expression levels of the CD36 gene between both
treated animal groups while no difference was observed in
the relative expression levels of PPARγ-responsive gene
SCARB1. Our results suggested differences at inflamma-
tory and oxidative levels between both treated animal
groups being less harmful in mice treated with RG than in
mice treated with LST. Studies have demonstrated PPARγ
induction in human monocytes following exposure to
oxLDL [9,50]. Notably new evidence has been provided
that Nrf2 plays an essential role in regulating CD36
expression [18,21]. Moreover, ox-LDLs are known to acti-
vate Nrf2-mediated gene responses [21]. Therefore, we
thought that in our experimental model some similar sit-
uation would justify the observed difference in the CD36
gene relative expression levels where Nrf2 could be impor-
tant. Thus, we performed gene expression analysis and
ChIP experiments and concluded that in HFHC-fed mice
treated with RG the smaller expression levels of the
hepatic CD36 gene were observed as opposed to HFHC-
fed mice treated with LST because RG prevents Nrf2-medi-
ated CD36 up-regulation. It has been reported that PPARγ
ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2)
(PGJ(2)), and troglitazone inhibits Nrf2-induced expres-
sion of the tromboxane synthase gene in macrophages
[51]. Because Nrf2 also regulates CD36 gene expression,
authors [21] suggested that the transcriptional regulators
PPARγ and Nrf2 may interact functionally to modulate
CD36 gene expression. As has been previously noted, we
demonstrated similarly preserved PPARγ activity in hyper-
cholesterolemic mice treated with RG or LST. Therefore
we deduced that RG seems to afford some additional anti-
aterogenic properties that prevent Nrf2-depedent CD-36
up-regulation which are partially independent of its
metabolizing properties as a PPARγ agonist.
We did not find statistically significant differences in the
eNOS relative gene expression levels between treated
groups with similarly preserved PPARγ activity. Authors
suggest that TZDs protective effects on vascular wall cells
are mediated by its ability to up-regulate eNOS gene
expression [52,53]. This effect of TZDs may explain its in
vivo vasodilating and blood pressure-lowering effects and,
at least for some TZDs, seems to be independent of their
PPARγ metabolizing effects. However, although the
molecular mechanisms by which TZDs increase NO
release are not completely worked out, they are likely to
depend on each particular TZD. For example Troglita-
zone, has an alpha-tocopherol (vitamin E) moiety that is
not present in other TZDs, and treatment of hepatocytes
with vitamin E and Troglitazone but not with RG led to an
inhibition of phosphoenolpyruvate carboxykinase gene
expression suggesting a PPARγ-independent, antioxidant-
related mechanism [54]. Goya et al [52] suggested that the
antioxidant and anti-inflammatory properties observed
following troglitazone administration to cells were linked
to the 6-hydroxychromonanes structure of troglitazone.
Jiang et al [55] proved that γ-tocopherol diminished pros-
taglandin E2 (PGE2) synthesis in macrophages. There-
fore, some TZDs share common anti-inflammatoryPage 12 of 15
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mediated by its structural relations with tocols. Gonon et
al [56] recently provide evidences that RG results in pro-
tection against myocardial contractile dysfunction
induced by ischemia reperfusion in mice receiving RG by
mediating eNOs protein phosphorilation without
increasing total eNOS concentration.
Our work has concentrated in analyzing the hepatic
expression of PPARγ and Nrf2 target genes and the valua-
tion of some serum markers. Although it is important to
go deep in the in vivo situation it is also important to rec-
ognize the differences of regulation of the expression of
genes regulated by PPAR and Nrf2 are tissue [21] and con-
text-dependent [57]. Thus, caution is required in the inter-
pretation of our results. Particularly, further in vivo
studies should be necessary to explore the role of Nrf2
transcription factor in modulating the progression of
foam cell formation and atherosclerosis.
Conclusion and Clinical Perspective
The present study indicates that the administration of RG
or LST to diet-induced atherosclerosis susceptible mice fed
a HFHC diet preserves in both groups the PPARγ activity.
RG seems to have antioxidant effects in addition to its
main metabolic activity in a manner that actually dimin-
ishes rather than increases the expression of the gene
CD36 by inhibiting its Nrf-2-dependent up-regulation.
Despite the favourable effects of RG observed in this
study, it must be acknowledged that the meta-analysis of
Nissen et al [58] on RG and cardiovascular risk raises the
hypothesis that TZDs treatments may increase the risk of
myocardial infarction and cardiovascular events. How-
ever, the general consensus is that this hypothesis needs
further evaluation [59]. Currently, animal and human
studies suggest that PPARγ ligands have anti-inflamma-
tory, antioxidant and vasculo-protective protective effects.
However, though there are similarities in TZD-induced
improvement in insulin sensitivity between experimental
models and humans, there are also substantial differ-
ences. Studies have focused on the role of adipocytokines
in metabolic control and their regulation by TZDs. Never-
theless, growing evidence suggests that the vasculo-protec-
tive effects of PPARγ ligands can be dissociated from its
metabolizing actions. Thus, there may be important
implications for the development of improved anti-ather-
ogenic and antidiabetic drug treatments. Additionally, the
identification of potential benefits associated with the
common molecular structure among these drugs will have
interesting clinical repercussions.
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